deltatrials
Completed PHASE3 NCT00360568

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Dyskinesias Parkinson's Disease Severe Motor Fluctuations
Interventions CADD-Legacy® 1400 ambulatory infusion pump J-tube Levodopa-carbidopa intestinal gel PEG tube
Updated 7 times since 2017 Last updated: Jan 12, 2015 Started: Jun 30, 2009 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

A PHASE3 clinical study on Dyskinesias and Parkinson's Disease, this trial is completed. The trial is conducted by AbbVie (prior sponsor, Abbott) and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie (prior sponsor, Abbott)
  • Quintiles, Inc.
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auckland, New Zealand, Baltimore, United States, Birmingham, United States, Bochum, Germany, Bradenton, United States, Bremerhaven, Germany, Burlington, United States, Chicago, United States, Cincinnati, United States, Cleveland, United States and 12 more location s